Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia

NCT00001790 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

120

Enrollment

NIH

Sponsor class

Conditions

Fever
Mycoses
Neutropenia

Interventions

DRUG: FK463

Sponsor

National Cancer Institute (NCI)